STOCK TITAN

SciSparc Enters into Definitive Agreement for the Acquisition of a Publicly Traded Company on the TSXV to which it will transfer its Advanced Clinical Stage Pharmaceutical Portfolio

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Neutral)

SciSparc (Nasdaq: SPRC) entered a definitive asset-and-share purchase agreement dated October 9, 2025, to transfer its advanced clinical-stage pharmaceutical portfolio and a ~51% stake in SciSparc Nutraceuticals into Miza III Ventures (TSXV: MIZA.P).

The agreement values the Target Assets at approximately US$11.6M and Miza enterprise value at approximately US$3.3M. SciSparc will receive 63,300,000 Miza common shares plus up to 48,000,000 contingent rights, yielding an expected post-close controlling interest of ~75%–84%. TSXV granted conditional approval; closing is anticipated on or about Oct 22, 2025. SciSparc may commit up to CAD1.0M via a 2-year convertible note at 7% and will receive 4,000,000 warrants exercisable at CAD0.25 for five years.

SciSparc (Nasdaq: SPRC) ha stipulato un accordo definitivo di acquisto di asset e azioni datato 9 ottobre 2025, per trasferire il suo portafoglio farmaceutico clinico avanzato e una partecipazione di circa il 51% in SciSparc Nutraceuticals a Miza III Ventures (TSXV: MIZA.P).

L'accordo valore i Target Assets a circa US$11,6M e la enterprise value di Miza a circa US$3,3M. SciSparc riceverà 63.300.000 azioni ordinarie Miza più fino a 48.000.000 diritti contingenti, con una quota di controllo post-chiusura prevista di ~75%–84%. TSXV ha concesso l'approvazione condizionale; la chiusura è prevista intorno al 22 ottobre 2025. SciSparc può impegnare fino a CAD1,0M tramite una nota convertibile a 2 anni al 7% e riceverà 4.000.000 warrant exercisabili a CAD0,25 per cinque anni.

SciSparc (Nasdaq: SPRC) entró en un acuerdo definitivo de compra de activos y acciones con fecha del 9 de octubre de 2025 para transferir su cartera farmacéutica clínica avanzada y aproximadamente el 51% de SciSparc Nutraceuticals a Miza III Ventures (TSXV: MIZA.P).

El acuerdo valora los Activos Objetivo en aproximadamente US$11,6M y la Enterprise Value de Miza en aproximadamente US$3,3M. SciSparc recibirá 63.300.000 acciones ordinarias de Miza más hasta 48.000.000 derechos contingentes, resultando en una participación de control post-cierre prevista de ~75%–84%. TSXV otorgó aprobación condicional; el cierre se espera alrededor del 22 de octubre de 2025. SciSparc podrá comprometer hasta CAD1,0M mediante una nota convertible a 2 años al 7% y recibirá 4.000.000 warrants exercitables a CAD0,25 durante cinco años.

SciSparc (Nasdaq: SPRC)는 2025년 10월 9일자로 확정 자산-주식 매매 계약을 체결하고, 첨단 임상단계의 의약 포트폴리오와 SciSparc Nutraceuticals의 약 51% 지분을 Miza III Ventures(TSXV: MIZA.P)로 이전합니다.

계약은 대상 자산을 대략 US$11.6백만, Miza의 기업가치를 대략 US$3.3백만으로 평가합니다. SciSparc는 63,300,000주 의 Miza 보통주를 받고 최대 48,000,000의 컨디션 권리를 받게 되며, 종료 후 예상되는 지배지분은 약 75%–84%입니다. TSXV는 조건부 승인을 부여했고 종결은 2025년 10월 22일경으로 예상됩니다. SciSparc는 2년 만기의 전환사채를 7%로 최대 CAD1.0백만까지 약정할 수 있으며, 5년간 행사 가능한 4,000,000개의 워런트를 CAD0.25에 받게 됩니다.

SciSparc (Nasdaq : SPRC) a conclu le 9 octobre 2025 un accord définitif d'achat d'actifs et d'actions afin de transférer son portefeuille pharmaceutique clinique avancé et une participation d'environ 51% dans SciSparc Nutraceuticals à Miza III Ventures (TSXV : MIZA.P).

L'accord évalue les Actifs Cibles à environ 11,6 millions de dollars américains et la valeur d'entreprise de Miza à environ 3,3 millions de dollars américains. SciSparc recevra 63 300 000 actions ordinaires de Miza et jusqu'à 48 000 000 droits éventuels, ce qui donne une participation majoritaire post-clôture d'environ 75%–84%. Le TSXV a accordé une approbation conditionnelle; la clôture est prévue aux alentours du 22 octobre 2025. SciSparc peut s'engager jusqu'à 1,0 million CAD via une note convertible sur 2 ans à 7% et recevra 4 000 000 de warrants exercables à 0,25 CAD pendant cinq ans.

SciSparc (Nasdaq: SPRC) hat am 9. Oktober 2025 eine endgültige Asset- und Aktienkaufvereinbarung unterzeichnet, um sein fortgeschrittenes klinisches Portfolio an Pharmazeutika und rund 51% der SciSparc Nutraceuticals an Miza III Ventures (TSXV: MIZA.P) zu übertragen.

Die Vereinbarung bewertet die Zielvermögenswerte mit ca. US$11,6 Mio und den Unternehmenswert von Miza mit ca. US$3,3 Mio. SciSparc wird 63.300.000 Miza Stammaktien erhalten sowie bis zu 48.000.000 bedingte Rechte, was nach Abschluss zu einer voraussichtlichen Mehrheitsbeteiligung von ca. 75%–84% führt. Der TSXV hat eine bedingte Zulassung erteilt; der Abschluss wird voraussichtlich um den 22. Oktober 2025 erfolgen. SciSparc kann sich bis zu CAD1,0 Mio über eine zweijährige wandelbare Anleihe zu 7% verpflichten und erhält 4.000.000 Warrants, die innerhalb von fünf Jahren zu CAD0,25 ausgeübt werden können.

SciSparc (ناسداك: SPRC) أبرمت اتفاقية شراء نهائية للأصول والأسهم بتاريخ 9 أكتوبر 2025 لنقل محفظتها من الأدوية في مراحلها السريرية المتقدمة ونحو 51% من SciSparc Nutraceuticals إلى Miza III Ventures (TSXV: MIZA.P).

تقوّم الاتفاق الأصول المستهدفة بنحو US$11.6 مليون وقيمة شركة ميزا بنحو US$3.3 مليون. ستتلقى SciSparc 63.300.000 سهماً عاديّاً من ميزا إضافة إلى حتى 48.000.000 حقوق مشروطة، مما يؤدي إلى حصة تحكّمية بعد الإغلاق تبلغ تقريباً 75%–84%. منحت TSXV الموافقة المشروطة؛ من المتوقع الإغلاق في نحو 22 أكتوبر 2025. يمكن لـ SciSparc الالتزام حتى CAD1.0 مليون عبر سند قابل للتحويل لمدة سنتين بفائدة 7% وسيتم منحها 4,000,000 warrants قابلة للإدراج خلال خمس سنوات وبسعر CAD0.25.

SciSparc(纳斯达克:SPRC) 已于 2025年10月9日 签署一项 definitive asset-and-share purchase agreement,将其处于临床阶段的先进药物组合以及对 SciSparc Nutraceuticals 约 51% 的股权转让给 Miza III Ventures(TSXV: MIZA.P)。

该协议将目标资产估值约为 US$11.6M,Miza 的企业价值约为 US$3.3M。SciSparc 将获得 63,300,000 股 Miza 普通股以及最多 48,000,000 项潜在权利,交易完成后预计的控股比例为 ≈75%–84%。TSXV 已给予有条件批准;预计于 2025年10月22日左右 完成。SciSparc 可通过一笔两年期、利率 7% 的可转换票据承诺最高达 CAD1.0M,并将获得可在五年内行使、执行价为 CAD0.25 的 4,000,000 份认股权证

Positive
  • Target Assets valued at US$11.6M
  • SciSparc to receive 63,300,000 Miza shares
  • Expected controlling interest of ~75%–84% post-close
  • TSXV granted conditional approval for the Proposed Transaction
  • Convertible note commitment up to CAD1,000,000 at 7% simple interest
Negative
  • Up to 48,000,000 contingent rights risk significant share dilution
  • Miza enterprise value US$3.3M versus assets US$11.6M
  • Payment warrants: 4,000,000 warrants at CAD0.25 create future dilution

Insights

SciSparc plans to transfer its advanced pharma portfolio to a TSXV-listed vehicle, receiving control of Miza and contingent consideration.

Under the Agreement, SciSparc will exchange its advanced clinical-stage pharmaceutical assets and its ~51% stake in SciSparc Nutraceuticals Inc. for 63,300,000 common shares of Miza III Ventures Inc. plus up to 48,000,000 contingent rights. The parties value the Target Assets at US$11.6 million and Miza’s enterprise at US$3.3 million, implying SciSparc will hold a controlling stake in Miza (approximately 75% to 84%) after closing.

The transaction changes the corporate vehicle for SciSparc’s assets and concentrates development and market exposure in a publicly traded TSXV entity expected to rebrand as NeuroThera Labs Inc. The agreement includes a potential unsecured convertible note commitment of up to CAD1,000,000 at 7 per annum with conversion at CAD0.25 per share capped at 4,000,000 shares, plus 4,000,000 five-year warrants exercisable at CAD0.25. This structure mixes equity, contingent rights and debt-like financing and will materially affect share count and potential dilution at Miza on conversion or warrant exercise.

Key dependencies and risks are explicit and binary: regulatory closing conditions including final TSXV approval, satisfaction of filing requirements and achievement of the pre-determined milestones that govern the contingent rights. Material balance-sheet effects include the reallocation of the US$11.6 million asset value into Miza equity and the issuance of securities that could dilute other Miza holders. Monitor the filing statement and the anticipated closing timing around October 22, 2025, the final TSXV approval, drawdown and terms of the convertible note, and the attainment of specified milestones tied to the 48,000,000 contingent rights within the stated milestones timeframe.

According to the agreement, SciSparc’s pharmaceuticals assets and equity stake in SciSparc Nutraceuticals Inc. are valued at approximately US$11.6 million

TEL AVIV, Israel, Oct. 15, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (Company” or SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today that on October 9, 2025, the Company entered into a definitive asset and share purchase agreement (the “Agreement”), pursuant to which it will receive a controlling interest in Miza III Ventures Inc. (“Miza”) (TSXV: MIZA.P), a publicly traded company on the TSX Venture Exchange (the “TSXV”) in Canada, and transfer to Miza its advanced clinical stage pharmaceutical portfolio and its equity stake of approximately 51% in SciSparc Nutraceuticals Inc. (collectively, the “Target Assets”).

According to the Agreement, the total enterprise value of Miza is approximately US$3.3 million (approximately CAD 4.5 million), taking into consideration its approximately US$1.0 million cash position, and the Target Assets are valued at approximately US$ 11.6 million (approximately CAD 15.8 million).

Pursuant to the Agreement, SciSparc will receive 63,300,000 common shares of Miza and up to 48,000,000 Miza contingent rights based on pre-determined milestones (the “Proposed Transaction”) and transfer to Miza the Target Assets. Following the closing of the Proposed Transaction, SciSparc is expected to hold a controlling interest in Miza, ranging from a minimum of approximately 75% to a maximum of approximately 84%. Following the closing, Miza is expected to change its name to “NeuroThera Labs Inc.” and to be active in both the pharmaceutical and supplemental sectors.

TSXV has conditionally approved the Proposed Transaction, and Miza has filed a filing statement in respect of the Proposed Transaction dated October 9, 2025, on Miza’s SEDAR+ profile (the “Filing Statement”). For a more detailed description of the Agreement and the Proposed Transaction, please see the Filing Statement.

Convertible Note

Upon the closing of the Proposed Transaction, subject to the approval of the TSXV, SciSparc, or a third-party on its behalf, intends to commit up to CAD1,000,000 (approximately US$716 thousand) in capital to Miza pursuant to an unsecured convertible note to be entered into, which shall mature on the two-year anniversary of the date of the issuance thereof (the “Maturity Date”) and shall bear interest at the simple rate of 7% per annum. The convertible note will be drawn down by Miza in its sole discretion. On the Maturity Date, the outstanding principal and accrued but unpaid interest under the convertible note shall be convertible into common shares of Miza, at the sole election of the holder, at a price of CAD 0.25 per share and up to a maximum of 4,000,000 common shares of Miza (the “Share Cap”), subject to customary anti-dilution adjustments. Upon conversion of the convertible note, for any principal amount or accrued interest not converted into shares due to being in excess of the Share Cap or rounding, Miza will pay the holder of the convertible note a cash amount of such outstanding balance.

Payment Warrants

At the Closing, Miza will issue to Scisparc 4,000,000 common share purchase warrants (the “Payment Warrants”). Each Payment Warrant will be exercisable to acquire one Miza common share at an exercise price of CAD 0.25 for a period of five years from the date of issuance thereof.

The Proposed Transaction, if it were to be finalized and completed, would align with SciSparc's strategy of creating value for its shareholders. Assuming all conditions to the closing of the Proposed Transaction are satisfied, the parties anticipate closing the Proposed Transaction on or around October 22, 2025. In due course, the parties will issue a further press release announcing the closing of the Proposed Transaction.

SciSparc’s pharmaceutical portfolio includes SCI-110 for treating persons with Tourette syndrome, which is subject to a phase IIb clinical trial, SCI-110 for treating persons with Alzheimer’s disease, the phase II clinical trial of which has been completed, and SCI-210 for treating children with autism, subject to a randomized, double-blind and placebo-controlled trial that commenced in the first quarter of 2024.

About SciSparc Ltd. (Nasdaq: SPRC):

SciSparc Ltd. is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists. SciSparc’s focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the Company is currently engaged in the following drug development programs based on THC and/or non-psychoactive CBD: SCI-110 for the treatment of Tourette syndrome, for the treatment of Alzheimer's disease and agitation; and SCI- 210 for the treatment of ASD and status epilepticus. The Company also owns a controlling interest in a subsidiary whose business focuses on the sale of hemp seed oil-based products on the Amazon.com Marketplace.

Forward-Looking Statements:

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. For example, SciSparc uses forward-looking statements when it discusses the closing of the Proposed Transaction and timing thereof, Miza’s activity in pharmaceutical and supplemental sectors post-closing, the Company’s intention to commit up to CAD1,000,000 (approximately US$716 thousand) in capital to Miza pursuant to an unsecured convertible note and the terms of the convertible note, and the belief that the Agreement would align with SciSparc's strategy of creating value for its shareholders. The Company may not complete the proposed transaction with Miza or, even if it does, it may not create shareholder value. Because such statements deal with future events and are based on SciSparc's current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of SciSparc could differ materially from those described in or implied by the statements in this press release. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading "Risk Factors" in SciSparc's Annual Report on Form 20-F, as amended, filed with the SEC on April 24, 2025, and in subsequent filings with the U.S. Securities and Exchange Commission. Except as otherwise required by law, SciSparc disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise.

Investor Contact:
IR@scisparc.com
Tel: +972-3-6167055


FAQ

What will SciSparc (SPRC) receive in the Miza (MIZA.P) transaction dated October 9, 2025?

SciSparc will receive 63,300,000 Miza common shares plus up to 48,000,000 contingent rights and 4,000,000 payment warrants.

How are the Target Assets and Miza valued in the Proposed Transaction?

The Target Assets are valued at approximately US$11.6M and Miza's enterprise value at approximately US$3.3M.

When is the SciSparc to Miza transfer expected to close and will Miza change its name?

Parties expect to close on or around October 22, 2025, and Miza is expected to change its name to NeuroThera Labs Inc..

Will SciSparc maintain control of Miza after closing of the Proposed Transaction?

Yes; SciSparc is expected to hold a controlling interest ranging from ~75% to ~84% following closing.

What convertible financing and warrant rights are included at closing of the transaction?

SciSparc may commit up to CAD1,000,000 via a 2-year convertible note at 7%; 4,000,000 warrants exercisable at CAD0.25 for five years will be issued.

How might the contingent rights and convertible instruments affect Miza shareholders?

The 48,000,000 contingent rights, 4,000,000 warrants, and potential note conversion may materially increase share count and dilute existing shareholders.
Scisparc

NASDAQ:SPRC

SPRC Rankings

SPRC Latest News

SPRC Latest SEC Filings

SPRC Stock Data

5.60M
1.62M
0%
0.5%
9.3%
Biotechnology
Healthcare
Link
Israel
Tel Aviv